US20060229327A1 - Therapeutic nucleosides - Google Patents

Therapeutic nucleosides Download PDF

Info

Publication number
US20060229327A1
US20060229327A1 US11/442,489 US44248906A US2006229327A1 US 20060229327 A1 US20060229327 A1 US 20060229327A1 US 44248906 A US44248906 A US 44248906A US 2006229327 A1 US2006229327 A1 US 2006229327A1
Authority
US
United States
Prior art keywords
compound
active ingredient
formula
hbv
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/442,489
Inventor
Dennis Liotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33304133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060229327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Emory University filed Critical Emory University
Priority to US11/442,489 priority Critical patent/US20060229327A1/en
Publication of US20060229327A1 publication Critical patent/US20060229327A1/en
Priority to US12/079,403 priority patent/US20080187580A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A45—HAND OR TRAVELLING ARTICLES
    • A45F—TRAVELLING OR CAMP EQUIPMENT: SACKS OR PACKS CARRIED ON THE BODY
    • A45F3/00—Travelling or camp articles; Sacks or packs carried on the body
    • A45F3/22—Hammocks; Hammock spreaders
    • A45F3/24—Stands; Supports
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the compound of formula (I) or a physiologically functional derivative thereof for use in the treatment or prophylaxis of a hepatitis B virus infection.
  • physiologically functional derivative is meant a pharmaceutically acceptable salt, amide, ester or salt of an ester of the compound of formula (I) or any other compound which upon administration to the recipient, is capable of providing (directly or indirectly) the said compound of formula (I) or an active metabolite or residue thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.

Description

  • The present invention relates to the use of a 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-cytosine derivative and physiologically functional derivatives thereof for the treatment of hepatitis 8 viral infections.
  • Hepatitis B virus (HBV) is a viral pathogen of major worldwide importance. HBV is most common in Asian Countries, and prevalent in sub-Saharan Africa. The virus is etiologically associated with primary hepatocellular carcinoma and is thought to cause 80% of the world's liver cancer. In the United States more than ten thousand people are hospitalized for HBV illness each year, an average of 250 die with fulminant disease. The United States currently contains an estimated pool of 500,000-1 million infectious carriers. Chronic active hepatitis will develop in over 25% of carriers and often progresses to cirrhosis. It is estimated that 5000 people die from HBV-related cirrhosis each year in the U.S.A. and that perhaps 1000 die from HBV-related liver cancer. Even when a universal HBV vaccine is in place, the need for effective anti-HBV compounds will continue. The large reservoir of persistently infected carriers, estimated at 220 million worldwide, will receive no benefit from vaccination and will continue at high risk for EBV-induced liver disease. This carrier population serves as the source of infection of susceptible individuals perpetuating the instance of disease particularly in endemic areas or high risk groups such as i.v. drug abusers and homosexuals. Thus, there is a great need for effective antiviral agents, both to control the chronic infection and reduce progression to hepatocellular carcinoma.
  • Clinical effects of infection with HBV range from headache, fever, malaise, nausea, vomiting, anorexia and abdominal pains. Replication of the virus is usually controlled by the immune response, with a course of recovery lasting weeks or months in humans, but infection may be more severe leading to persistent chronic liver disease as outlined above. In “Viral Infections of Humans” (second edition, Ed. Evans, A. S. (1982) Plenum Publishing Corporation, New York), Chapter 12 describes the etiology of viral hepatitis infections.
  • European Patent Specification 0 382 526 discloses certain 1,3-oxathio-lane nucleoside analogues which are effective in inhibiting the replication of human immunodeficiency virus (HIV).
  • Since the priority date of this patent application, the following items have been published: Doong, S. L. et al., Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogs, Proc. Natl. Acad. Sci. USA, 88 (19), 8495-9 (1991); Liotta, D. C. and Choi, W. B., Synthesis of BCH-189 and related compounds, PCT Appl. WO 91/11186; Soudeyns, H. et al., Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), Antimicrob. Agents Chemother., 35 (7), 1386-90 (1991 and Choi, W. B. et al., In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs, J. Am. Chem. Soc., 113 (24), 9377-9 (1991).
  • We have now surprisingly found that a 1-(2-(hydroxymethyl)-1,3-oxath-iolan-5-yl)-cytosine derivative of formula I
    Figure US20060229327A1-20061012-C00001
    namely 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine or a pharmaceutically acceptable salt, ester or other physiologically functional derivatives thereof have potent activity against HBV.
  • It should be noted that the compound of formula (I) contains two chiral centers and therefore exists in the form of two pairs of optical isomers (i.e. enantiomers) and mixtures thereof including racemic mixtures. Thus, the compound of formula (I) may be either a cis or a trans isomer or mixtures thereof. Each cis and trans isomer can exist as one of two enantiomers or mixtures thereof including racemic mixtures. All such isomers and mixtures thereof including racemic mixtures and tautomeric forms of the compound of formula (I) are within the scope of the invention. The cis isomers of the compound of formula (I) are preferred.
  • According to one feature of the present invention we provide the compound of formula (I) or a physiologically functional derivative thereof for use in the treatment or prophylaxis of a hepatitis B virus infection. According to a further feature of the present invention we provide the use of the compound of formula (I) or a physiologically functional derivative thereof, in the manufacture of a medicament for the treatment or prophylaxis of a hepatitis B virus infection.
  • In a further aspect of the present invention there is included a method for the treatment or prophylaxis of a hepatitis B virus infection in a host, for example, a mammal such as a human which comprises treating the host with a therapeutically effective amount of the compound of formula (I) or a physiologically functional derivative thereof.
  • By “physiologically functional derivative” is meant a pharmaceutically acceptable salt, amide, ester or salt of an ester of the compound of formula (I) or any other compound which upon administration to the recipient, is capable of providing (directly or indirectly) the said compound of formula (I) or an active metabolite or residue thereof.
  • Preferred esters in accordance with the invention include carboxylic acid esters in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl e.g. n-propyl, t-butyl, n-butyl, alkoxyalkyl (e.g. methoxymethyl), arylalkyl (e.g. benzyl), aryloxyalkyl (e.g. phenoxymethyl), and aryl (e.g. phenyl); sulfonate esters such as alkyl- or arylalkylsulfonyl (e.g. methanesulfonyl); amino acid esters (e.g. L-valyl or L-isoleucyl); dicarboxylic acid esters (e.g. hemisuccinate); and 5′-mono- di- or tri-phosphate esters. The phosphate esters may be further esterified by, for example, a C1-20 alcohol or reactive derivative thereof, or by a 2,3-di(C6-24)acyl glycerol. Any alkyl moiety present in such esters advantageously contains 1 to 18 carbon atoms, particularly 1 to 4 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group optionally substituted e.g. by halogen, C1-4 alkyl, C1-4 alkoxy or nitro.
  • The above-mentioned pharmaceutically acceptable amides of the compound of formula (I) include those derivatives wherein the cytosine amino group is present in the form of an amide, e.g. —NHCOR where R is C1-6 alkyl or aryl (e.g. phenyl optionally substituted by halogen, C1-4 alkyl, C1-4 alkoxy, nitro or hydroxyl).
  • Examples of pharmaceutically acceptable salts according to the invention include base salts, e.g. derived from an appropriate base, such as alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium) salts, ammonium and NX4 + (wherein K is C1-4 alkyl). Pharmaceutically acceptable acid addition salts include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.
  • The amount of the compound of formula (I) (hereinafter also referred to as the “active ingredient”) or physiologically functional derivative thereof which is required in a medication to achieve the desired effect will depend on a number of factors, in particular the specific application, the nature of the particular compound used, the mode of administration and the condition of the patient. In general a suitable dose will be in the range of 3.0 to 120 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg per kilogram body weight per day and most preferably in the range 15 to 60 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.
  • Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active ingredient of from about 1 to about 75 μM, preferably about 2 to 50 μM, most preferably about 3 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 100 mg/kg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.
  • In the manufacture of a medicament according to the invention, hereinafter referred to as a “formulation”, the compound of formula (I) or a physiologically functional derivative thereof herein as “active ingredient”, is typically admixed with, inter alia, one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents.
  • The formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
  • A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
  • Formulations suitable for oral use as described above may also include buffering agents designed to neutralize stomach acidity. Such buffers may be chosen from a variety of organic or inorganic agents such as weak acids or bases admixed with their conjugated salts.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injections solutions which may contain anti-oxidants, buffers. bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, as liposomes or other microparticulate systems which are designed to target the compounds to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
  • It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.
  • The compound of formula I may be prepared for example by:
  • a) reacting an optionally protected 5-F-cytosine compound with a 1,3-oxathiolane of formula (IIA)
    Figure US20060229327A1-20061012-C00002
      • wherein R1 is hydrogen or a hydroxy protecting group and L is a leaving group; or
  • b) reacting a compound of formula (IIB)
    Figure US20060229327A1-20061012-C00003
      • (wherein R1 is as defined above and R1 a is an amino protecting group) with a fluorinating agent serving to introduce a fluorine atom in the 5-position of the cytosine ring; or
  • c) reacting a compound of formula (IIC)
    Figure US20060229327A1-20061012-C00004
  • (wherein R1 is as defined above) with an agent serving to convert the oxo group in the 4-position of the uracil ring to an amino group; any remaining protecting groups being removed for example by acid or base hydrolysis to produce the desired product.
  • With regard to process a), the hydroxy protecting group includes protecting groups such as acyl (e.g. acetyl), arylacyl (e.g. benzoyl or substituted benzoyl), trityl or monomethoxytrityl, benzyl or substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. The 5-F-cytosine compound may be optionally protected with silyl, e.g. trimethyl silyl groups. Such groups may be removed in conventional manner. The leaving group L is a leaving group typical: of those known in the art of nucleoside chemistry e.g. halogen such as chlorine or bromine, alkoxy such as methozy or ethoxy or acyl such as acetyl or benzoyl.
  • The reaction in process a) may be effected in an organic solvent (e.g. 1,2-dichloroethane or acetonitrile) in the presence of a Lewis acid such as stannic chloride or trimethylsilyl triflate.
  • Compounds of formula IIA may be obtained from a suitably protected 2-hydroxyacetaldehyde of formula (III),
    R1OCH2CHO  (III)
    wherein R1 is defined above, as described in Can. J. Research, 8, 129 (1933) and European Patent Specification 0 382 526. Reaction of compounds of formula (III) with a mercaptoacetal HSCH2CH(OR)2, wherein R is C1-4 alkoxy such as HSCH2CH(OC2H5)2, known in the art (Chem. Ber. 85:924-932, 1952), yields compounds of formula IIA wherein L is OR (alkoxy) e.g. methoxy or ethoxy. Alternatively, compounds of formula IIA, wherein L is alkoxy, may be converted to compounds of formula IIA wherein L is halogen or acyl by methods known in the art of carbohydrate chemistry.
  • Compounds of formula (III) may be prepared from 1,2-0-isopropylidene glycerol by introduction of R1 (e.g. trisubstituted silyl, benzyl or trityl) and removal of the isopropylidene group with mild acid (e.g. aqueous formic or acetic acid) or zinc bromide in acetonitrile, followed by oxidation of the alcohol group with aqueous periodate.
  • With regard to process b), the 5-fluoro substituent may be introduced by methods known in the art (N. J. Robins, et al., in Nucleic Acid Chemistry, Part 2, L. B. Townsend and R. S. Tipson, editors, J. Wiley and Sons, New York, 895-900 (1978) and references therein; R. Duschinsky in Nucleic Acid Chemistry, Part 1, L. B. Townsend and R. S. Tipson, editors, J. Wiley and Sons, New York, 43-46 (1978) and references therein). The fluorinating agent may be, for example, trimethylhypofluorite in fluorotrichloromethane.
  • With regard to process c), the compound of formula (IIC) is advantageously treated with 1,2,4-triazole, advantageously together with 4-chlorophenyl dichlorophosphate, to form the corresponding 4-(1,2,4-triazolyl) compound which is then converted to the desired 4-amino (cytidine) compound by reaction with for example methanol.
  • The starting materials of formula (IIB) and (IIC) may be prepared for example by reaction of an appropriate (optionally protected) base with a compound of formula IIA in an analogous manner to that described in process a). 5-Fluorouracil and 5-fluorocytosine are commercially available from Aldrich Chemical Co., Milwaukee, Wis. 53233, USA.
  • Separation of the (±)-cis and (±)-trans isomers for example in a protected form, may be accomplished by chromatography on silica gel with mixtures of organic solvents such as ethyl acetate/methanol, ethylacetate/hexane or dichloromethane/methanol. Any protecting group may then be removed using the appropriate reagent for each group.
  • The compound of formula (I) may be converted into a pharmaceutically acceptable esters and amides by reaction with an appropriate acylating agent, for example, an acid halide or anhydride serving to acylate the 5′-OH and 4-NH2 groups. The acyl group may then be removed selectively from one or other of the 5′-OH and 4-NH2 groups. For, example, treatment of the diacylated compound under acidic conditions, eg. a Lewis acid such as zinc bromide in methanol, removes the 4N-acyl group to yield the corresponding 5′-OR ester where treatment of the diacylated compound under alkaline conditions, eg. with sodium methoxide removes the 5′-OH acyl group to yield the corresponding 4N-amide. The acyl groups can also be removed selectively by treatment with commercially available esterase or lipase enzymes, eg. pig liver esterase or pancreatic lipase, or by treatment in accordance with methods described in U.S. Pat. No. 5,071,983. The compound of formula (I) may be converted into a pharmaceutically acceptable salt thereof in a conventional manner, for example, by treatment with an appropriate base. An ester or salt of a compound of formula (I) may be converted into the parent compound, for example, by hydrolysis.
  • For a better understanding of the invention, the following Examples are given by way of illustration.
    • EXAMPLE 1 cis-1-(2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine
  • Method A: (±)-cis and (±)-trans 2-benzoyloxymethyl-5-(N4-acetyl-cyto-sin-1-yl)-1,3-oxathiolane are prepared and separated to the (±)-cis and (±) trans isomers as described in European Patent Specification 0 382 526. (See U.S. Pat. No. 5,047,407.) The (±)-cis isomer is fluorinated with trifluoromethyl hypofluorite in fluorotrichloromethane (CCI3F) and chloroform at −78° C., according to the method of Robins, et al. Nucleic Acid Chemistry, Part 2, 895-900, 1978. The N4-acetyl and 2-benzoyl groups are removed with dimethylamine in ethanol, and the product, (±)-cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine, is isolated.
  • Method B: (±)-cis and (±)-trans-2-benzoyloxymethyl-5-(uracil-1-yl)-1,3-oxathiolane are prepared as described in EP 0 382 526. After deprotection of the 2-hydroxyl group with saturated methanolic ammonia, the isomers are separated on silica gel using EtOAc/HeCH as eluant (EP 0 382 526). The (±)-cis isomer is reacted with acetic anhydride in pyridine at room temperature to give the 2-acetate. Solvent is removed in vacuo at <30° C. The 2-acetate is then dissolved in CHCl3 and washed with aqueous sodium bicarbonate. The separated organic layer is dried, and CHCl3 is evaporated in vacuo. (±)-cis-2-Acetyloxymethyl-5-(uracil-1-yl)-1,3-oxathiolane is fluorina-ted as described above (method A) by the method of Robins et al. Conversion of the 5-F-uracil base to the 5-F-cytosine base is carried out by preparation of the 4-(1,2,4-triazol-1-yl) derivative according to the methods of C. B. Reese, J. Chem. Soc., Perkins I, 1171, 1984 and W. L. Sung, Nucleic Acids Res. 9:6139, 1981, using 1,2,4-triazole and 2 equivalents of 4-chlorophenyldichlorophosphate in dry pyridine at ambient temperature. This conversion is followed by reaction with methanol previously saturated with ammonia at 0° C., and the 2-acetate is hydrolyzed to give (±)-cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine.
    • Pharmaceutical Formulations
  • In the following formulation Examples, the “Active Ingredient” is cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine.
    • EXAMPLE 2 Tablet Formulations
  • The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.
    Formulation A
    mg/tablet mg/tablet
    (a) Active ingredient 250 250
    (b) Lactose B.P. 210 26
    (c) Povidone B.P. 15 9
    (d) Sodium Starch Glycollate 20 12
    (e) Magnesium Stearate 5 3
    500 300
  • Formulation B
    mg/tablet mg/tablet
    (a) Active ingredient 250 250
    (b) Lactose 150 —
    (c) Avicel PH 101 60 26
    (d) Povidone B.P. 15 9
    (e) Sodium Starch Glycollate 20 12
    (f) Magnesium Stearate 5 3
    500 300
  • Formulation C
    mg/tablet
    Active ingredient 100
    Lactose 200
    Starch 50
    Povidone 5
    Magnesium Stearate 4
    359
  • The following formulations, D and E, are prepared by direct compression of the admixed ingredients. The lactose in formulation E is of the direct compression type (Dairy Crest—“Zeparox”).
    Formulation D
    mg/tablet
    Active ingredient 250
    Pregelatinized Starch NF15 150
    400
  • Formulation E
    mg/tablet
    Active ingredient 250
    Lactose 150
    Avicel 100
    500
    • Formulation F (Controlled Release Formulation)
  • The formulation is prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression.
    mg/tablet
    (a) Active ingredient 500
    (b) Hydroxypropylmethylcellulose 112
    (Methocel K4M Premium)
    (c) Lactose B.P. 53
    (d) Povidone B.P. 28
    (e) Magnesium Stearate 7
    700
  • Drug release takes place ever a period of about 6-8 hours and is complete after 12 hours.
    • EXAMPLE 3 Capsule Formulations Formulation A
  • A capsule formulation is prepared by admixing the ingredients of Formulation D in Example 2 above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner.
    Formulation B
    mg/capsule
    (a) Active ingredient 250
    (b) Lactose B.P. 143
    (c) Sodium Starch Glycollate 25
    (d) Magnesium Stearate 2
    420
  • Formulation C
    mg/capsule
    (a) Active ingredient 250
    (b) Macrogol 4000 B.P. 350
    600
  • Formulation D
    mg/capsule
    Active ingredient 250
    Lecithin 100
    Arachis Oil 100
    450
  • Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.
    • Formulation E (Controlled Release Capsule)
  • The following controlled release capsule formulation is prepared by extruding ingredients a, b and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with controlled-release membrane (d) and filled into a two-piece, hard gelatin capsule.
    mg/capsule
    (a) Active ingredient 250
    (b) Microcrystalline Cellulose 125
    (c) Lactose B.P. 125
    (d) Ethyl Cellulose 13
    513
    • EXAMPLE 4 Injectable Formulation
  • Formulation A
    Active ingredient 0.200 g
    Hydrochloric acid solution, O.1 M, or 4.0 to 7.0
    Sodium hydroxide solution, 0.1 M q.s. to pH
    Sterile water q.s. to 10 mL
  • The active ingredient is dissolved in most of the water (35° C.-40° C.) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10 mL amber glass vial (type 1) and sealed with sterile closures and overseals.
    Formulation B
    Active ingredient 0.125
    Sterile, pyrogen-free, pH 7 phosphate q.s. to 25 mL
    Buffer,
    • EXAMPLE 5
  • Intramuscular injection
    Active ingredient 0.20 g
    Benzyl Alcohol 0.10 g
    Glycofurol 75 1.45 g
    Benzyl Alcohol q.s. to 3.00 mL
  • The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 mL. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 mL amber glass vials (type 1).
    • EXAMPLE 6
  • Syrup
    Active ingredient 0.25 g
    Sorbitol Solution 1.50 g
    Glycerol 2.00 g
    Sodium Benzoate 0.005 g
    Flavor, Peach 17.42.316 9 0.0125 mL
    Purified Water q.s. to 5.00 mL
  • The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbitol solution and finally the flavor. The volume is made up with purified water and mixed well.
    • EXAMPLE 7
  • Suppository
    mg/suppository
    Active ingredient 250
    Hard Fat, B.P. (Witepsol H15 - Dynamit Nobel) 1770
    2020
  • One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45° C. maximum. The active ingredient is sifted through a 200 μm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until smooth dispersion is achieved. Maintaining the mixture at 45° C., the remaining Witepsol His is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250 μm stainless steel screen and, with continuous stirring,. is allowed to cool to 40° C. At a temperature of 38° C. to 40° C., 2.02 g of the mixture is filled into suitable, 2 mL plastic molds. The suppositories are allowed to cool to room temperature.
    • EXAMPLE 8
  • Pessaries
    mg/pessary
    Active ingredient 250
    Anhydrate Dextrose 380
    Potato Starch 363
    Magnesium Stearate 7
    1000
  • The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.
    • EXAMPLE 9 Antiviral Activity Against Hepatitis B Virus (HBV)
  • The compound cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluoro-cytosine, was tested as described below.
  • The human HBV producer cell line of HePG2, 2.2.15, described and characterized by Sells et al., PNAS 84:1005, 1987 and J. Virol. 62:2836, 1988, has been shown to share many characteristics of the HBV chronically infected hepatocyte. It is infectious as demonstrated by the ability to cause disease in chimpanzees. This cell line was utilized in vitro to identify compounds with anti-HBV activity.
  • To test compounds for antiviral activity, monolayer cultures were treated with compound, 50-2001M for ten days. Supernatant media containing extracellular virion DNA (Dane particles) were harvested on days three, six and ten, treated with proteinase K (1 mg/mL) and sodium dodecyl sulfate (1%), and incubated at 50° C. for one hour. DNA was extracted with equal volumes of phenol followed by chloroform and then precipitated by ammonium acetate and propanol. The DNA precipitate was dissolved and collected on nitrocellulose using the procedure of Schleicher and Schuell (S & S, 10 Optical Ave., Keene, N.H. 03431, Publication No. 700, 1987), and treated as described by Southern, J. Mol. Biol. 98:503, 1975. Cells were harvested, and the intracellular DNA was obtained after cell lysis with guanidine isothiocyanate. The intracellular DNA was handled in the same manner as the extracellular DNA. After precipitation by ammonium acetate and propanol, the intracellular DNA precipitate was dissolved, cut by restriction endonuclease, Hind III, applied to agarose gel and then treated as described by Southern to determine the quantity of replicative intermediate forms. The antiviral effect of the compound was determined by measuring at least a 100-fold reduction of the amount of Dane particles extruded into the culture medium and a similar decrease in the intracellular replicative intermediates.
  • The results are given below:
    Effect of cis-1-(2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)-5-
    fluorocytosine on HBV Production in 2.2.15 Cell Cultures
    Intracellular HBV DNA* HBV DNA in Culture Medium
    Treatment (pg/μg cell DNA) (pg/mL)++
    Compound Replicative Day
    (μM) Integrated Monomer intermediate Day 0 Day 3 Day 6 10
    A. untreated 1.1 2.0 81 58 67 93 77
    cells 0.9 2.3 77 89 110 100 88
    100 1.9 0.8 2 64 11 3 0
    1.5 1.9 1 34 19 2 0
    B. untreated 1.5 1.9 110 65 44 86 71
    cells 1.0 2.3 67 90 120 80 82
    100 1.6 0.8 1 90 16 0 0
    1.0 0.7 1 74 10 0 0

    *Analysis of intracellular HBV DNA (Dane particles) was 24 hours following the 10th day of treatment.

    ++A “zero” indicates an undetectable level of HBV DNA, sensitivity cutoff was 0.1 pg/mL

Claims (3)

1. A method of treating an HBV infection in a human having an HBV infection comprising orally administering a pharmaceutical composition suitable for oral administration containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I)
Figure US20060229327A1-20061012-C00005
or a pharmaceutically acceptable salt thereof to said HBV infected human.
2. The method of claim 1, in which the compound or salt is administered in a tablet or capsule.
3. A method of treating an HBV infection in a human having an HBV infection comprising injecting said HBV infected human with a sterile liquid pharmaceutical composition containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I)
Figure US20060229327A1-20061012-C00006
or a pharmaceutically acceptable salt thereof.
US11/442,489 1991-03-06 2006-05-26 Therapeutic nucleosides Abandoned US20060229327A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/442,489 US20060229327A1 (en) 1991-03-06 2006-05-26 Therapeutic nucleosides
US12/079,403 US20080187580A1 (en) 1991-03-06 2008-03-26 Therapeutic nucleosides

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
GB9104741.5 1991-05-02
GB9109505.9 1991-05-02
US77607291A 1991-10-11 1991-10-11
US84630392A 1992-03-05 1992-03-05
US45139295A 1995-05-26 1995-05-26
US09/007,502 US6812233B1 (en) 1991-03-06 1998-01-15 Therapeutic nucleosides
US10/888,387 US7053100B2 (en) 1991-03-06 2004-07-09 Therapeutic nucleosides
US11/442,489 US20060229327A1 (en) 1991-03-06 2006-05-26 Therapeutic nucleosides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/888,837 Continuation US6931679B1 (en) 2004-07-09 2004-07-09 Foldable stand for a hammock

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/079,403 Continuation US20080187580A1 (en) 1991-03-06 2008-03-26 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
US20060229327A1 true US20060229327A1 (en) 2006-10-12

Family

ID=33304133

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/007,502 Expired - Lifetime US6812233B1 (en) 1991-03-06 1998-01-15 Therapeutic nucleosides
US10/888,387 Expired - Fee Related US7053100B2 (en) 1991-03-06 2004-07-09 Therapeutic nucleosides
US11/442,489 Abandoned US20060229327A1 (en) 1991-03-06 2006-05-26 Therapeutic nucleosides
US12/079,403 Abandoned US20080187580A1 (en) 1991-03-06 2008-03-26 Therapeutic nucleosides

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/007,502 Expired - Lifetime US6812233B1 (en) 1991-03-06 1998-01-15 Therapeutic nucleosides
US10/888,387 Expired - Fee Related US7053100B2 (en) 1991-03-06 2004-07-09 Therapeutic nucleosides

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/079,403 Abandoned US20080187580A1 (en) 1991-03-06 2008-03-26 Therapeutic nucleosides

Country Status (1)

Country Link
US (4) US6812233B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
KR20090053867A (en) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 Compositions and methods for combination antiviral therapy
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4204466A (en) * 1977-11-24 1980-05-27 Fr. Winkler Kg Plant for the automatic production of Arabic flat bread
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4874751A (en) * 1985-03-16 1989-10-17 Burroughs Wellcome Co. Antibacterial treatment
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5151426A (en) * 1989-02-08 1992-09-29 Biochem Pharma Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5486520A (en) * 1991-05-20 1996-01-23 Biochempharma, Inc. 1,3-oxathiolanes useful in the treatment of hepatitis
US5538975A (en) * 1991-08-01 1996-07-23 Biochem Pharma, Inc. 1,3-oxathiolane nucleoside compounds and compositions
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US20020083872A1 (en) * 2000-10-24 2002-07-04 Peter Tippl Drive mechanism with holder for material to be sewn and sewing machine with such a drive mechanism
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
ATE81978T1 (en) 1985-03-16 1992-11-15 Wellcome Found USE OF 3'-AZIDO-3'-DEOXYTHYMIDINE IN THE TREATMENT OR PREVENTION OF HUMAN RETROVIRUS INFECTIONS.
EP0206497B1 (en) 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
US5159067A (en) 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5081010A (en) 1989-02-09 1992-01-14 Eastman Kodak Company Extraction composition, test kit and their use to extract or determine herpes simplex viral antigen
NZ233197A (en) 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
AU5659990A (en) 1989-05-15 1990-12-18 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of treatment of hepatitis
ES2091948T3 (en) 1990-11-13 1996-11-16 Iaf Biochem Int 1,3-OXATIOLANES SUBSTITUTED WITH ANTIVIRIC PROPERTIES.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CZ285232B6 (en) 1991-05-16 1999-06-16 Glaxo Group Limited Antiviral mixtures and pharmaceutical preparation containing thereof
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4204466A (en) * 1977-11-24 1980-05-27 Fr. Winkler Kg Plant for the automatic production of Arabic flat bread
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4874751A (en) * 1985-03-16 1989-10-17 Burroughs Wellcome Co. Antibacterial treatment
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5151426A (en) * 1989-02-08 1992-09-29 Biochem Pharma Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5210085A (en) * 1990-02-01 1993-05-11 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5814639A (en) * 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5892025A (en) * 1990-02-01 1999-04-06 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5914400A (en) * 1990-02-01 1999-06-22 Emory University Method and compositions for the synthesis of BCH-189 and related compounds
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5486520A (en) * 1991-05-20 1996-01-23 Biochempharma, Inc. 1,3-oxathiolanes useful in the treatment of hepatitis
US5538975A (en) * 1991-08-01 1996-07-23 Biochem Pharma, Inc. 1,3-oxathiolane nucleoside compounds and compositions
US5618820A (en) * 1991-08-01 1997-04-08 Biochem Pharma, Inc. 1,3-oxathiolane nucleoside analogues and methods for using same
US20020083872A1 (en) * 2000-10-24 2002-07-04 Peter Tippl Drive mechanism with holder for material to be sewn and sewing machine with such a drive mechanism

Also Published As

Publication number Publication date
US6812233B1 (en) 2004-11-02
US7053100B2 (en) 2006-05-30
US20040242610A1 (en) 2004-12-02
US20080187580A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
EP0574487B1 (en) Use of 5-fluoro-2&#39;-deoxy-3&#39;-thiacytidine for the treatment of hepatitis b
IE84129B1 (en) Therapeutic nucleosides
US6107288A (en) Antiviral nucleoside combination
US20080187580A1 (en) Therapeutic nucleosides
WO1992016215A1 (en) Use of 3&#39;-azido-2&#39;,3&#39;-dideoxyguanosine for the treatment of hepatitis b
WO1992019246A1 (en) Use of a 1,3-oxathiolan derivative for the treatment of hepatitis b infection
US5637574A (en) Therapeutic nucleosides
CA2439322A1 (en) Therapeutic nucleosides
NZ264990A (en) Use of 1-(2-(hydroxymethyl))-1,3-oxathiolan-5-yl)cytosine derivatives to prepare medicaments and methods of treatment of hepatitas b virus infections
IE85820B1 (en) Use of 5 - fluoro -2&#39;deoxy-3&#39; thiacytidine for the treatment of hepatitis B

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION